Neurons activate T cells to create a supportive microenvironment for brain tumor formation and growth

Defining the neuroimmune-cancer cell axis

Like 0 Comment
Read the paper

For the past 25 years, my laboratory has developed and employed genetically engineered mice to understand why brain tumors form in children with the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome1. Using these authenticated preclinical mouse models of NF1-associated optic gliomas (low-grade astrocytomas of the optic nerves)2, we showed that microglia, macrophage-like cells in the brain, produce growth factors necessary for tumor development, proliferation, and vision loss3, 4, 5, 6. However, it was not clear how microglia get activated to control tumor pathogenesis.

This all changed thanks to Reviewer #3.

To create a transplantable low-grade glioma model, Dr. Yi-Hsien Chen, a postdoctoral fellow in our group, isolated cancer stem cells from Nf1 optic glioma mice, and showed that they could form tumors when injected into the brains of naïve immunocompetent mice7. We were very excited about this finding, and submitted the paper for review. We were surprised that one of the reviewers insisted that we repeat these experiments using immunocompromised mice, similar to what other investigators have historically employed for human brain tumor xenograft studies. At first blush, this seemed like a strange request, as we had already demonstrated tumor formation in mice with a normal immune system. To our amazement, when Yi-Hsien injected these optic glioma stem cells into athymic mice lacking functional T cells, no tumors were observed!  

The finding that T cells were required for brain tumor formation was exciting, and prompted another postdoctoral fellow, Dr. Yuan Pan, to confirm and extend these observations. Yuan went on to demonstrate that the inability of athymic mice to support optic glioma formation resulted from impaired microglia function, including reduced expression of Ccr2 and Ccl5, both of which are required for Nf1 optic glioma growth. She further demonstrated that reduced Ccr2 and Ccl5 expression by athymic microglia could be restored by soluble factors produced by activated T cells8.

While these studies established a critical role for T cells in microglia-mediated glioma formation and growth, how T cells became activated and how they created a supportive tumor microenvironment remained unknown. Enter Dr. Xiaofan (Gary) Guo, a graduate student in our laboratory who had previously shown that T cells and microglia are drawn into the tumor microenvironment by chemokines secreted from the glioma cells themselves9. In our latest report10, Gary and his colleagues nicely demonstrated that T cell entry into the brain is required for optic glioma growth, and that, upon activation, T cells produce Ccl4, which in turn induces microglia to secrete Ccl5, the growth factor necessary for optic glioma growth11. Moreover, Gary discovered that neurons were the cells responsible for activating T cells, thus establishing a neuroimmune-cancer cell circuit.  

We are very excited about these findings, as they have important implications for the field.   

First, the fact that nerve cells are active participants in brain tumor development and growth adds to our growing appreciation of the role of neurons in cancer – ushering in the new field of Cancer Neuroscience12. Researchers in our team are now investigating the role of neurons in dictating human and mouse nervous system tumor formation and progression. Second, our studies demonstrate that T cells are key regulators of the brain tumor microenvironment, prompting us to explore the idea that T cells can alter microglia function in the brain, both in health and in the setting of central nervous system disease13. Third, since we showed that T cells are recruited into the optic nerve (brain) from the blood, we hypothesize that T cells may serve as integrators of risk factors for brain disorders, including gliomas. Current studies in the laboratory are focused on understanding how environmental exposures and systemic diseases impact on  brain tumor formation and progression in mice14, 15.  

I want to thank the wonderful trainees whom I have had the pleasure of mentoring, and look forward to similarly exciting new breakthroughs from future members of our team. You can learn more by following us on Twitter (@GutmannLab) and the Gutmann laboratory website (https://gutmannlab.wustl.edu).

References 

1.   Campen CJ, Gutmann DH. Optic Pathway Gliomas in Neurofibromatosis Type 1. J Child Neurol 33, 73-81 (2018).  

2.   Hegedus B, et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 68, 1520-1528 (2008).  

3.   Daginakatte GC, Gianino SM, Zhao NW, Parsadanian AS, Gutmann DH. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res 68, 10358-10366 (2008).  

4.   Daginakatte GC, Gutmann DH. Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16, 1098-1112 (2007).  

5.   Pong WW, Higer SB, Gianino SM, Emnett RJ, Gutmann DH. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol 73, 303-308 (2013).  

6.   Toonen JA, Solga AC, Ma Y, Gutmann DH. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology. J Exp Med 214, 17-25 (2017).  

7.   Chen YH, et al. Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. Cell Rep 10, 1899-1912 (2015).  

8.   Pan Y, et al. Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth. 32, 491-496 (2018).  

9.   Guo X, Pan Y, Gutmann DH. Genetic and genomic alterations differentially dictate low-grade glioma growth through cancer stem cell-specific chemokine recruitment of T cells and microglia. Neuro Oncol,  21, 1250-1262 (2019).  

10. Guo X PY, Xiong M, Sanapala S, Anastasaki C, Cobb O, Dahiya S, Gutmann DH. Midkine activation of CD8+ cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth. Nat Commun In press, (2020).  https://rdcu.be/b3Ud

11. Solga AC, et al. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth. Neoplasia 17, 776-788 (2015).  

12. Monje M, et al. Roadmap for the Emerging Field of Cancer Neuroscience. Cell 181, 219-222 (2020).  

13. Wright-Jin EC, Gutmann DH. Microglia as Dynamic Cellular Mediators of Brain Function. Trends Mol Med 25, 967-979 (2019).  

14. Johnson KJ, Zoellner NL, Gutmann DH. Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1. Cancer Epidemiol 42, 53-59 (2016).  

15. Porcelli B, Zoellner NL, Abadin SS, Gutmann DH, Johnson KJ. Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1. Fam Cancer 15, 301-308 (2016).  

Go to the profile of David H. Gutmann, MD, PhD, FAAN

David H. Gutmann, MD, PhD, FAAN

Donald O. Schnuck Family Professor, Vice Chair for Research Affairs, Department of Neurology; Director, Neurofibromatosis (NF) Center, Washington University

David H. Gutmann received his undergraduate, graduate (PhD) and medical (MD) degrees from the University of Michigan, where he trained in immunogenetics in the laboratory of Dr. John Niederhuber. During his residency in Neurology at the University of Pennsylvania, he worked with Dr. Kenneth Fischbeck who sparked his interest in neurogenetics. He then returned to the University of Michigan for research fellowship training in Human Genetics with Dr. Francis Collins. During that time, he identified the neurofibromatosis type 1 (NF1) protein and began to elucidate its function as a RAS regulator. In late 1993, Dr. Gutmann was recruited to Washington University, becoming a full professor in 2001 and the Donald O. Schnuck Family Professor in 2002. He established the St. Louis Children’s Hospital Neurofibromatosis Clinical Program in 1994 and the Washington University Neurofibromatosis Center in 2004. His laboratory is currently focused on understanding the genomic, molecular and cellular basis for nervous system problems affecting children and adults with NF1 using both human induced pluripotent stem cells and novel genetically engineered mouse strains. They have used these preclinical models to define the cellular origins of tumors, the contribution of the tumor microenvironment, and the major growth control pathways that dictate brain development in NF. Moreover, the use of NF1 as an experimental model system has revealed numerous insights into the basic neurobiology of human disease, including tumor-stroma dependencies in the cancer ecosystem, the impact of the germline mutation on phenotypic expression, the role of sexual dimorphism in clinical outcome, and the mechanisms underlying cell type-specific, brain region-distinct, and signaling pathway diversity. Dr. Gutmann has published over 450 peer-reviewed manuscripts, and has been recognized for his achievements with numerous awards, including the 2012 Children’s Tumor Foundation Frederich von Recklinghausen Lifetime Achievement Award, the 2013 Washington University Distinguished Faculty Research Award, the 2014 Riley Church Lectureship, the 2017 Alexander von Humboldt Award, the 2019 Society for Neuro-Oncology Abhijit Guha Award, the 2020 National Neurofibromatosis Network Advocate of Hope Award, and the 2020 American Academy of Neurology Neuro-Oncology Investigator Award. He is a Fellow of the American Academy of Neurology, and recently completed his tenure as a member of the National Institute of Neurological Disorders and Stroke Advisory Council.

No comments yet.